Please wait a minute...
文章检索
预防医学  2025, Vol. 37 Issue (8): 789-793,798    DOI: 10.19485/j.cnki.issn2096-5087.2025.08.007
  综述 本期目录 | 过刊浏览 | 高级检索 |
猴痘病原学和流行病学研究进展
刘珊, 张劲松, 张文利, 王贺, 朱文烨 综述, 沙琨 审校
海军军医大学卫生勤务学系,上海 200433
Research progress on the etiology and epidemiology of monkeypox
LIU Shan, ZHANG Jingsong, ZHANG Wenli, WANG He, ZHU Wenye, SHA Kun
Faculty of Military Health Service, Naval Medical University, Shanghai 200433, China
全文: PDF(1446 KB)  
输出: BibTeX | EndNote (RIS)      
摘要 猴痘是由猴痘病毒感染引起的一种既往局限于非洲流行的人畜共患传染病。自2022年起猴痘迅速在全球范围广泛传播,波及全球130个国家和地区,世界卫生组织分别于2022年和2024年宣布其为国际关注的突发公共卫生事件。猴痘病毒变异速度加快,流行毒株呈多样化,儿童、男男性行为人群为主要高危人群,无症状感染及非典型轻度皮疹等增加鉴别诊断难度,对猴痘的诊疗和防控提出挑战。本文检索1958年1月—2025年1月有关猴痘的文献,对猴痘的病原学特征、流行特征、临床特征和防治策略等方面进行综述,为预防和治疗猴痘提供依据。
服务
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章
刘珊
张劲松
张文利
王贺
朱文烨
沙琨
关键词 猴痘猴痘病毒流行特征治疗预防    
Abstract:Monkeypox is a zoonotic disease caused by the monkeypox virus, which was previously limited to epidemics in Africa. Since 2022, monkeypox has rapidly spread worldwide, affecting 130 countries and regions. The World Health Organization declared it a public health emergency of international concern, in 2022 and 2024, respectively. The monkeypox virus has exhibited accelerated mutation rates, with diverse circulating strains. Children and men who have sex with men have emerged as the primary high-risk group. Additionally, the increase in asymptomatic infections and atypical mild rashes has complicated differential diagnosis, posing entirely challenges to the diagnosis, treatment, and prevention and control of monkeypox. This article reviews the research progress on the etiological characteristics, epidemiological features, clinical manifestations, and prevention and treatment strategies of monkeypox by retrieving the literature on monkeypox from January 1958 to January 2025, so as to provide the basis for the prevention and treatment of monkeypox.
Key wordsmonkeypox    monkeypox virus    epidemiological characteristics    treatment    prevention
收稿日期: 2025-03-21      修回日期: 2025-07-28      出版日期: 2025-08-10
中图分类号:  R511  
基金资助:国家自然科学基金项目(12131020); 上海市教育委员会人工智能专项(2024RGYB004)
作者简介: 刘珊,硕士,主要从事生物信息学、数据挖掘研究工作
通信作者: 沙琨,E-mail:kunie@smmu.edu.cn   
引用本文:   
刘珊, 张劲松, 张文利, 王贺, 朱文烨, 沙琨. 猴痘病原学和流行病学研究进展[J]. 预防医学, 2025, 37(8): 789-793,798.
LIU Shan, ZHANG Jingsong, ZHANG Wenli, WANG He, ZHU Wenye, SHA Kun. Research progress on the etiology and epidemiology of monkeypox. Preventive Medicine, 2025, 37(8): 789-793,798.
链接本文:  
https://www.zjyfyxzz.com/CN/10.19485/j.cnki.issn2096-5087.2025.08.007      或      https://www.zjyfyxzz.com/CN/Y2025/V37/I8/789
[1] PETERSEN E,KANTELE A,KOOPMANS M,et al.Human monkeypox:epidemiologic and clinical characteristics,diagnosis,and prevention[J].Infect Dis Clin North Am,2019,33(4):1027-1043.
[2] SUN Y H,NIE W J,TIAN D D,et al.Human monkeypox virus:epidemiologic review and research progress in diagnosis and treatment[J/OL].J Clin Virol,2024,171[2025-07-28].https://doi.org/10.1016/j.jcv.2024.105662.
[3] PATEL A,BILINSKA J,TAM J C H,et al.Clinical features and novel presentations of human monkeypox in a central London centre during the2022 outbreak:descriptive case series[J/OL].BMJ,2022,378[2025-07-28].https://doi.org/10.1136/bmj-2022-072410.
[4] World Health Organization.Global mpox trends[EB/OL].[2025-07-28].https://worldhealthorg.shinyapps.io/mpx_global/#3_Global_situation_update.
[5] World Health Organization.WHO Director-general's statement at the press conference following IHR Emergency Committee regarding the multi-country outbreak of monkeypox[EB/OL].[2025-07-28].https://www.who.int/director-general/speeches/detail/who-director-general-s-statement-on-the-press-conference-following-IHR-
emergency-committee-regarding-the-multi--country-outbreak-of-monkeypox--23-july-2022.
[6] World Health Organization.WHO Director-General declares mpox outbreak a public health emergency of international concern[EB/OL].[2025-07-28].https://www.who.int/news/item/14-08-2024-who-director-general-declares-mpox-outbreak-a-public-health-emergency-of-international-concern.
[7] YI X M,LEI Y L,LI M,et al.The monkeypox virus-host interplays[J/OL].Cell Insight,2024,3(5)[2025-07-28].https://doi.org/10.1016/j.cellin.2024.100185.
[8] GIORGI F M,POZZOBON D,DI MEGLIO A,et al.Genomic and transcriptomic analysis of the recent Mpox outbreak[J].Vaccine,2024,42(7):1841-1849.
[9] BERTHET N,DESCORPS-DECLÈRE S,BESOMBES C,et al.Genomic history of human monkey pox infections in the Central African Republic between2001 and 2018[J/OL].Sci Rep,2021,11(1)[2025-07-28].https://doi.org/10.1038/s41598-021-92315-8.
[10] MOSS B.Poxvirus entry and membrane fusion[J].Virology,2006,344(1):48-54.
[11] KARUMATHIL S,RAVEENDRAN N T,GANESH D,et al.Evolution of synonymous codon usage bias in West African and Central African strains of monkeypox virus[J/OL].Evol Bioinform Online,2018,14[2025-07-28].https://doi.org/10.1177/1176934318761368.
[12] LADNYJ I D,ZIEGLER P,KIMA E.A human infection caused by monkeypox virus in Basankusu Territory,Democratic Republic of the Congo[J].Bull World Health Organ,1972,46(5):593-597.
[13] BUNGE E M,HOET B,CHEN L,et al.The changing epidemiology of human monkeypox-a potential threat? A systematic review[J/OL].PLoS Negl Trop Dis,2022,16(2)[2025-07-28].https://doi.org/10.1371/journal.pntd.0010141.
[14] VON MAGNUS P,ANDERSEN E K,PETERSEN K B,et al.A pox-like disease in cynomolgus monkeys[J].Acta Pathol Microbiol Scand,1959,46(2):156-176.
[15] MARENNIKOVA S S,SELUHINA E M,MAL'CEVA N N,et al.Isolation and properties of the causal agent of a new variola-like disease(monkeypox)in man[J].Bull World Health Organ,1972,46(5):599-611.
[16] OLAWADE D B,WADA O Z,FIDELIS S C,et al.Strengthening Africa's response to Mpox(monkeypox):insights from historical outbreaks and the present global spread[J/OL].Sci One Health,2024,3[2025-07-28].https://doi.org/10.1016/j.soh.2024.100085.
[17] ANDERSON M G,FRENKEL L D,HOMANN S,et al.A case of severe monkeypox virus disease in an American child:emerging infections and changing professional values[J].Pediatr Infect Dis J,2003,22(12):1093-1098.
[18] YINKA-OGUNLEYE A,ARUNA O,OGOINA D,et al.Reemergence of human monkeypox in Nigeria,2017[J].Emerg Infect Dis,2018,24(6):1149-1151.
[19] ALAKUNLE E,KOLAWOLE D,DIAZ-CÁNOVA D,et al.A comprehensive review of monkeypox virus and mpox characteristics[J/OL].Front Cell Infect Microbiol,2024,14[2025-07-28].https://doi.org/10.3389/fcimb.2024.1360586.
[20] World Health Organization.Fifth meeting of the International Health Regulations(2005)(IHR)emergency committee on the multi-country outbreak of mpox(monkeypox)[EB/OL].[2025-07-28].https://www.who.int/news/item/11-05-2023-fifth-meeting-of-the-international-health-regulations-(2005)-
[21] Africa Centres For Disease Control And Prevention.Africa CDC epidemic intelligence weekly report:August 2024[EB/OL].[2025-07-28].https://africacdc.org/download/africa-cdc-weekly-event-based-surveillance-report-august-2024.
[22] 重庆市卫生健康委员会.重庆市发现1例境外输入猴痘病例[EB/OL].[2025-07-28].https://wsjkw.cq.gov.cn/zwgk_242/wsjklymsxx/ylws_266434/jbfk_266438/gzxx_266440/202209/t20220916_11120694.html.
[23] 国家卫生健康委员会.将猴痘纳入乙类传染病管理的政策解读[EB/OL].[2025-07-28].https://www.nhc.gov.cn/ylyjs/gzdt/202309/c3c8f10115e84cdd9f4fe5aa97effad2.shtml.
[24] 中国疾病预防控制中心.我国发现一起猴痘病毒Ⅰb亚分支聚集性疫情[EB/OL].[2025-07-28].https://www.chinacdc.cn/jksj/jksj01/202501/t20250109_303772.html.
[25] DUTTA S,GHOSH R,DASGUPTA I,et al.Monkeypox:a comprehensive review on mutation,transmission,pathophysiology,and therapeutics[J/OL].Int Immunopharmacol,2025,146[2025-07-28].https://doi.org/10.1016/j.intimp.2024.113813.
[26] DASHRAATH P,NIELSEN-SAINES K,RIMOIN A,et al.Monkeypox in pregnancy:virology,clinical presentation,and obstetric management[J].Am J Obstet Gynecol,2022,227(6):849-861.
[27] POLAND G A,KENNEDY R B,TOSH P K.Prevention of monkeypox with vaccines:a rapid review[J].Lancet Infect Dis,2022,22(12):349-358.
[28] RIMOIN A W,MULEMBAKANI P M,JOHNSTON S C,et al.Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo[J].Proc Natl Acad Sci USA,2010,107(37):16262-16267.
[29] OGOINA D,DAMON I,NAKOUNE E.Clinical review of human mpox[J].Clin Microbiol Infect,2023,29(12):1493-1501.
[30] SATAPATHY P,MOHANTY P,MANNA S,et al.Potentially asymptomatic infection of monkeypox virus:a systematic review and meta-analysis[J/OL].Vaccines(Basel),2022,10(12)[2025-07-28].https://doi.org/10.3390/vaccines10122083.
[31] ANDREI G,SNOECK R.Differences in pathogenicity among the mpox virus clades:impact on drug discovery and vaccine development[J].Trends Pharmacol Sci,2023,44(10):719-739.
[32] World Health Organization.Clinical management and infection prevention and control for monkeypox:interim rapid response guidance[EB/OL].[2025-07-28].https://iris.who.int/bitstream/handle/10665/355798/WHO-MPX-Clinical-and-IPC-2022.1-chi.pdf.
[33] HUDU S A,ALSHRARI A S,AL QTAITAT A,et al.VP37 protein inhibitors for mpox treatment:highlights on recent advances,patent literature,and future directions[J/OL].Biomedicines,2023[2025-07-28].https://doi.org/10.3390/biomedicines11041106.
[34] ALMEHMADI M,ALLAHYANI M,ALSAIARI A A,et al.A glance at the development and patent literature of tecovirimat:the first-in-class therapy for emerging monkeypox outbreak[J/OL].Viruses,2022,14(9)[2025-07-28].https://doi.org/10.3390/v14091870.
[35] DESAI A N,THOMPSON G R 3rd,NEUMEISTER S M,et al.Compassionate use of tecovirimat for the treatment of monkeypox infection[J].JAMA,2022,328(13):1348-1350.
[36] SIEGRIST E A,SASSINE J.Antivirals with activity against mpox:a clinically oriented review[J].Clin Infect Dis,2023,76(1):155-164.
[37] WANG X L,GU Z X,SHENG S G,et al.The current state and progress of mpox vaccine research[J].China CDC Weekly,2024,6(7):118-125.
[38] World Health Organization.WHO prequalifies the first vaccine against mpox[EB/OL].[2025-07-28].https://www.who.int/zh/news/item/13-09-2024-who-prequalifies-the-first-vaccine-against-mpox.
[39] 王雪琛,李涛,王慧,等.猴痘病毒的研究进展概述[J].病毒学报,2024,40(1):169-182.
WANG X C,LI T,WANG H,et al.Research progress on mpox virus[J].Chin J Virol,2024,40(1):169-182.(in Chinese)
[40] 国家疾病预防控制局.猴痘防控方案[EB/OL].[2025-07-28].https://www.ndcpa.gov.cn/jbkzzx/c100081/1715172949319086080/dD5BTOPg.pdf.
[1] 吕婧, 徐欣颖, 乔颖异, 石兴龙, 岳芳, 刘营, 程传龙, 张宇琦, 孙继民, 李秀君. 浙江省发热伴血小板减少综合征流行特征及影响因素分析[J]. 预防医学, 2026, 38(1): 10-14.
[2] 夏文玲, 高强, 李阳, 蔡奔, 万春雨, 崔志贞, 张正, 潘恩春. 2011—2024年淮安市发热伴血小板减少综合征流行特征和时空聚集性分析[J]. 预防医学, 2026, 38(1): 55-59,65.
[3] 方叶冬, 孙芳红, 邓建凯, 邱芳芳, 王晓臻, 周祖木. 瑞安市成年居民慢性病危险因素聚类分析[J]. 预防医学, 2026, 38(1): 60-65.
[4] 吴卉, 徐秋敏, 任治兴, 阴媛, 翟前前, 姚来顺. 2020—2024年长春市水痘流行特征和时空聚集性分析[J]. 预防医学, 2026, 38(1): 66-70,74.
[5] 陶桃, 张海芳, 凡鹏飞, 李秋华, 陈晓蕾. 丽水市老年肺结核患者治疗转归的影响因素分析[J]. 预防医学, 2025, 37(9): 892-896,902.
[6] 姜艳, 李锦成, 许纯, 杨科佼, 杨文彬, 徐胜. 扬州市MSM人群艾滋病非职业暴露后预防知晓率调查[J]. 预防医学, 2025, 37(9): 903-906,912.
[7] 凌红, 汪娜, 宋琴, 徐昊. 2009—2023年黄浦区肺结核流行特征和时空聚集性分析[J]. 预防医学, 2025, 37(9): 937-940.
[8] 张俊杰, 罗超, 姜立坤, 张慧颖. 2015—2024年哈尔滨市百日咳流行特征分析[J]. 预防医学, 2025, 37(9): 941-944.
[9] 李克, 庞志峰, 吴晓虹, 王诚, 何瑶, 唐慧玲. 2007—2024年金华市钩端螺旋体病流行特征分析[J]. 预防医学, 2025, 37(8): 818-821.
[10] 魏志云, 罗小飞, 于颖洁, 贺亚琴, 杨倩, 窦强. 山西省布鲁氏菌病流行特征与空间聚集性分析[J]. 预防医学, 2025, 37(8): 842-845.
[11] 苏德华, 陈向阳, 李君, 赵丽娜, 张鹤美, 朱婷婷, 胡文雪, 赖江宜. 温州市新报告HIV/AIDS病例抗病毒治疗及时性分析[J]. 预防医学, 2025, 37(8): 804-808.
[12] 徐莉, 刘萍, 卞宇旬, 陈圆媛, 李鑫娜, 周乐. 扬州市新报告50岁及以上HIV/AIDS病例抗病毒治疗前耐药分析[J]. 预防医学, 2025, 37(8): 779-782,788.
[13] 冷雪, 傅淑琴, 舒纪为, 谭启龙, 李科峰. 舟山市带状疱疹首诊病例特征分析[J]. 预防医学, 2025, 37(7): 701-704.
[14] 李克, 庞志峰, 吴晓虹, 唐慧玲. 2005—2023年金华市猩红热流行特征和时空聚集性分析[J]. 预防医学, 2025, 37(7): 705-709.
[15] 刘艳, 张子喆, 王雨达, 刘光涛, 沈建勇. 2013—2023年湖州市手足口病流行特征[J]. 预防医学, 2025, 37(7): 718-721.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed